TELO2

Across TCGA pan-cancer cohorts, TELO2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TELO2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TELO2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TELO2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where TELO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.346	0.856	<.001	71	view →
PDAC	OS	Median	III,IV	0.333	0.887	<.001	25	view →
HNSC	OS	Quartile	All	0.127	0.788	.045	12	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	6	view →
LUAD	DFS	Median	II,III,IV	0.962	0.710	.012	2	view →
UCEC	DFS	Median	All	1.000	0.939	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TELO2–CCRCC (OS)

Open the CCRCC breakdown →